L-carnosine as an adjuvant to fluvoxamine in treatment of obsessive compulsive disorder: A randomized double-blind study (original) (raw)

Randomized, Double-Blind, Placebo-Controlled Trial of N-Acetylcysteine Augmentation for Treatment-Resistant Obsessive-Compulsive Disorder

Daniel Las Casas

The Journal of clinical psychiatry, 2017

View PDFchevron_right

Glutamate-modulating drugs as novel pharmacotherapeutic agents in the treatment of obsessive-compulsive disorder

John Krystal

NeuroRx : the journal of the American Society for Experimental NeuroTherapeutics, 2006

View PDFchevron_right

Serotonin reuptake blockers: Is there preclinical evidence for their efficacy in obsessive-compulsive disorder?

Jan Mos

Human Psychopharmacology: Clinical and Experimental, 1991

View PDFchevron_right

Efficacy of N-Acetylcysteine Augmentation on Obsessive Compulsive Disorder: A Multicenter Randomized Double Blind Placebo Controlled Clinical Trial

ali firoozabadi

Iranian journal of psychiatry, 2017

View PDFchevron_right

Comparison of Saffron and Fluvoxamine in the Treatment of Mild to Moderate Obsessive-Compulsive Disorder: A Double Blind Randomized Clinical Trial

Shahin Akhondzadeh

Iranian journal of psychiatry, 2017

View PDFchevron_right

Obsessive compulsive disorder and the glutamatergic system

Catherine Nyuthe

Current Opinion in Psychiatry, 2014

View PDFchevron_right

Investigational and Experimental Drugs to Treat Obsessive-Compulsive Disorder

Chiara Cecchelli

Journal of Experimental Pharmacology, 2021

View PDFchevron_right

Efficacy of combination of fluoxetine and cognitive behavioral therapy and fluoxetine alone for the treatment of obsessive compulsive disorder

Noor Giasuddin

Pakistan journal of pharmaceutical sciences, 2013

View PDFchevron_right

Adjunctive glycine in the treatment of obsessive-compulsive disorder in adults

Melissa Benedict, Laura Panek

Journal of Psychiatric Research, 2009

View PDFchevron_right

Randomized Controlled Crossover Trial of Ketamine in Obsessive-Compulsive Disorder: Proof-of-Concept

Donna Vermes

Neuropsychopharmacology, 2013

View PDFchevron_right

Fluvoxamine and sulpiride in comorbid obsessive-compulsive disorder and gilles de la tourette syndrome

Mark George

Human Psychopharmacology: Clinical and Experimental, 1993

View PDFchevron_right

In vivo effects of ketamine on glutamate-glutamine and gamma-aminobutyric acid in obsessive-compulsive disorder: Proof of concept

Dikoma C Shungu

Psychiatry Research: Neuroimaging, 2015

View PDFchevron_right

Glutamatergic medications as adjunctive therapy for moderate to severe obsessive-compulsive disorder in adults: a systematic review and meta-analysis

Shayan Kashefinejad

BMC Pharmacology and Toxicology

View PDFchevron_right

N-Acetylcysteine Add-On Treatment in Refractory Obsessive-Compulsive Disorder: A Randomized, Double-Blind, Placebo-Controlled Trial

Mohammad Haghighi

2012

View PDFchevron_right

On the Pharmacotherapy of Obsessive—Compulsive Disorder: Is a Consensus Possible?

François Borgeat

The Canadian Journal of Psychiatry, 2000

View PDFchevron_right

A pilot study of biological predictors of treatment outcome in obsessive-compulsive disorder

Donald Klein

Biological Psychiatry, 1993

View PDFchevron_right

N-acetylcysteine augmentation in serotonin reuptake inhibitor refractory obsessive-compulsive disorder

John Krystal, Ben Kelmendi

Psychopharmacology, 2006

View PDFchevron_right

Exposure therapy, fluvoxamine, or combination treatment in obsessive-compulsive disorder: One-year followup

Isaac Marks

Psychiatry Research, 1993

View PDFchevron_right

Plasma fluvoxamine levels and OCD symptoms/response in adult patients

Gabriele Massimetti

Human Psychopharmacology: Clinical and Experimental, 2012

View PDFchevron_right

Anterior cingulate glutamate–glutamine levels predict symptom severity in women with obsessive–compulsive disorder

Christos Pantelis

Australian and New Zealand Journal of Psychiatry, 2008

View PDFchevron_right

Long–term course and outcome of obsessive–compulsive patientsafter cognitive–behavioral therapy in combination with eitherfluvoxamine or placebo

Michael Rufer

European Archives of Psychiatry and Clinical Neuroscience, 2005

View PDFchevron_right

Low-dose risperidone augmentation of fluvoxamine treatment in obsessive-compulsive disorder: a double-blind, placebo-controlled study

Stefano Erzegovesi

European Neuropsychopharmacology, 2005

View PDFchevron_right

Effectiveness of fluoxetine on various subtypes of obsessive-compulsive disorder

Alireza Farnam

Archives of Iranian medicine, 2008

View PDFchevron_right

Double-blind comparison of fluoxetine versus clomipramine in the treatment of obsessive compulsive disorder

María Hernández

European Neuropsychopharmacology, 1996

View PDFchevron_right

Pharmacotherapy for obsessive-compulsive disorder

Michael Jenike, Darin Dougherty

Advances in Psychiatric Treatment, 2011

View PDFchevron_right

A Double-Blind, Randomized, Controlled Trial of Fluoxetine Plus Quetiapine or Clomipramine Versus Fluoxetine Plus Placebo for Obsessive-Compulsive Disorder

Lorrin Koran

Journal of Clinical Psychopharmacology, 2011

View PDFchevron_right

Psychopharmacological treatment of Obsessive-Compulsive Disorder (OCD)

Dorian Lamis

Current neuropharmacology, 2018

View PDFchevron_right

Current trends in drug treatment of obsessive–compulsive disorder

Dan Stein

Neuropsychiatric Disease and Treatment, 2010

View PDFchevron_right

N-Acetylcysteine Add-On Treatment in Refractory Obsessive-Compulsive Disorder

Hamidreza Roohafza

Journal of Clinical Psychopharmacology, 2012

View PDFchevron_right

Emerging drugs to treat obsessive–compulsive disorder

Stefano Pallanti

Expert Opinion on Emerging Drugs, 2013

View PDFchevron_right

Role of Glutamatergic System in Obsessive-Compulsive Disorder with Possible Therapeutic Implications

Jiri Horacek

Pharmacopsychiatry, 2017

View PDFchevron_right